Under the terms of the agreements, Arno has acquired the rights to several small molecules for the treatment of cancer, including OSU-03012 (NSC D728209) and OSU-HDAC42 (NSC D736012). Arno will pay development based milestones and royalties based on sales of the licensed products.
Scott Fields, president and chief medical officer of Arno, said: “We look forward to moving these molecules into the clinic and to hopefully bringing their benefits to patients who need them as soon as possible.”